about
Statins and the risk of lung cancer: a meta-analysisStatins and fibrates for preventing melanomaThe effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]The "Statinth" wonder of the world: a panacea for all illnesses or a bubble about to burst.Is peroxisome proliferation an obligatory precursor step in the carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)?Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trialsStatins as the new aspirin. Conclusions from the heart protection study were prematureCholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trialsGenomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of actionCancer risk in older people receiving statin therapy: a meta-analysis of randomized controlled trialsTreating the patient or the population? Part 1. Judging the benefit of treatment of individual patients.Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch databaseStatin use and cancer risk: a comprehensive reviewStatin use and risk of liver cancer: an update meta-analysis.Statin use and risk of pancreatic cancer: a meta-analysis.Statin use and risk of breast cancer: a meta-analysis of observational studies.Statin use and risk of bladder cancer: a meta-analysis.Statins are associated with reduced risk of gastric cancer: a meta-analysis.Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trialsCurrent practice in the treatment of hyperlipidaemias.Statins and risk of cancer: a systematic review and metaanalysis.Statin use and female reproductive organ cancer risk in a large population-based setting.Should we lower cholesterol as much as possible?Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials.Key scientific issues in the health risk assessment of trichloroethyleneEffect of the statin atorvastatin on intracellular signalling by the prostacyclin receptor in vitro and in vivo.Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database.Statin use and risk of primary liver cancer in the Clinical Practice Research Datalink.Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trialStatin use and the risk of colorectal cancer: a population-based case-control studyShort term statin treatment improves survival and differentially regulates macrophage-mediated responses to Staphylococcus aureusSimvastatin is protective during Staphylococcus aureus pneumoniaMeta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomesThe toxicology of HMG-CoA reductase inhibitors: prediction of human risk.Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies.Lipid-lowering agents that cause drug-induced hepatotoxicity.Statin use and breast cancer risk in a large population-based setting.Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis.Recent developments in the treatment of atherosclerosis.Statin use and cancer risk: an epidemiologic review.
P2860
Q21559688-FDF89B64-4D22-4946-A6C0-7D05443163B4Q24245521-B42FED52-D689-4016-A540-F4F5DCB9DFB4Q24793837-CBCDD172-3BD4-4312-A651-FB0EAB962AE6Q24796000-5953628C-EB09-4F99-9A31-31C9F3D7592EQ24812167-A43C12C5-2DFE-4794-A815-47B72B75DB54Q26864662-33F49878-4B96-4D07-8E9C-20D7AB95CB87Q28192659-2EDD3866-5C4D-458B-B7E9-967F500C2D28Q28345598-6ABD6BD7-CA9B-4004-ACE2-CBEEA860A2B3Q28541142-5F90B598-B8A2-48B2-A973-CB99DA6BFE28Q28821882-C40115E3-3D8A-448A-B605-D24208BA27F5Q33729111-ABB38000-D142-4654-BAD8-B194CD737064Q33867311-577D8B96-93FF-43D3-830E-9568CB08CC7AQ34021312-4F5FD65A-C805-417D-AFC3-3F013096BB01Q34198230-EB45D327-9624-4BA8-995C-8747414472D5Q34273115-76E40941-7D40-44B8-A706-479B94D81D82Q34288756-5B8A3C0F-184F-42E6-B1D3-A67587E02BA6Q34325144-13FAC59C-6628-4AB9-AF2B-B76BD4D4A338Q34349560-E5195D12-65C7-4EFD-82B9-E09C4B64E9DEQ34428524-CAA85F3C-E887-4CC9-89A5-88FA8B32A1C3Q34515467-AA225435-9D86-4840-840A-0D5FE68B8264Q34585294-4B71ED0A-9ACE-4AE9-A625-BFE8ACF8317CQ34585472-007F8FC6-8D80-4071-8739-9004AAA60215Q34654691-E965B6A4-59DA-4785-9F90-5EBB80EF62C1Q35035835-37F5D7A9-3256-48D6-9384-E20317DA7690Q35039295-8842EA44-0ECA-46E2-9A20-24EE9A8A64CCQ35047687-2AE26645-F9D9-44C7-B4F3-41DA6A8ABBB2Q35069176-01535056-BF93-4DD3-8A22-800E222F3954Q35152907-4E115057-EF1A-427B-BB7F-58137C984243Q35622529-8811C44B-4041-45E6-83F7-4FB10C500AECQ35627285-6C9B2457-3A15-4D00-8A65-4B6782060A5BQ35743888-C2949E77-E5EF-43BD-829D-32D3D8ADD406Q35747672-99C1210D-AC0E-41F8-953B-6C37AF54E7D2Q35826088-775D51CC-203B-43DA-AB3F-52D469BB1473Q35927194-8BAA459D-7F30-4D96-BE03-48D24FBAE75FQ36024705-B7973085-5395-4943-81FE-5B1566D8D8DFQ36103339-43CE6DFA-0796-48F3-9C21-B61DD8D1C88DQ36120856-97C9CF32-19DC-4088-8420-7614DA5D8738Q36243281-841F73B8-20A5-444E-8038-EBC1B1C49DC7Q36434617-4F743652-F5AE-4EA9-8B05-AA4C1B9DBAA2Q36508082-1D7DF11A-6FF2-4D12-B41F-7542CD6EE856
P2860
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Carcinogenicity of lipid-lowering drugs.
@ast
Carcinogenicity of lipid-lowering drugs.
@en
Carcinogenicity of lipid-lowering drugs.
@nl
type
label
Carcinogenicity of lipid-lowering drugs.
@ast
Carcinogenicity of lipid-lowering drugs.
@en
Carcinogenicity of lipid-lowering drugs.
@nl
prefLabel
Carcinogenicity of lipid-lowering drugs.
@ast
Carcinogenicity of lipid-lowering drugs.
@en
Carcinogenicity of lipid-lowering drugs.
@nl
P1476
Carcinogenicity of lipid-lowering drugs.
@en
P2093
S B Hulley
T B Newman
P356
10.1001/JAMA.1996.03530250059028
P407
P577
1996-01-01T00:00:00Z